Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02116543 · ClinicalTrials.gov registry record · Phase 1
TD-6450 MAD Study in HCV Infected Subjects
A Phase 1 study of Hepatitis C and HCV, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT02116543: Completed Phase 1 study of Hepatitis C and HCV, sponsored by Theravance Biopharma.
NCT02116543 is a Phase 1 study of Hepatitis C and HCV that has completed, run by Theravance Biopharma. The registered enrollment target is 47 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02116543, a Phase 1 study of Hepatitis C and HCV, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
This proof of concept study is designed to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of TD-6450 in treatment naïve subjects with GT-1, GT-2 or GT-3 chronic HCV.
Primary Outcome
Number, type, severity, and association of treatment emergent adverse events.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TD-6450
Study Locations (1)
Texas
- Texas Liver Institute - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
What the finished NCT02116543 record still lists
NCT02116543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02116543 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02116543 about?
NCT02116543 is a clinical study titled "TD-6450 MAD Study in HCV Infected Subjects". This proof of concept study is designed to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of TD-6450 in treatment naïve subjects with GT-1, GT-2 or GT-3 chronic HCV.
What is the current status of trial NCT02116543?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2014-05. Estimated completion is 2014-11.
What conditions does trial NCT02116543 study?
This clinical trial studies the following conditions: Hepatitis C, HCV.
What interventions are being tested in trial NCT02116543?
The interventions under investigation include: Placebo (DRUG), TD-6450 (DRUG).
Who is sponsoring clinical trial NCT02116543?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02116543 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02116543's enrollment target sits among peer trials
47 76th of 106 higher than 30 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
COMPLETED · Phase 1
-
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 1
-
Open-Label Hepatic Impairment Study
COMPLETED · Phase 1
-
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
COMPLETED · Phase 1
-
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia